Shoreline Biosciences is at the forefront of developing next-generation cellular immunotherapies utilizing induced pluripotent stem cells (iPSCs). The company focuses on creating iPSC-derived natural killer (iNK) cells and macrophages (iMACs) through advanced techniques in iPSC differentiation, genetic engineering, and immune cell biology. Their proprietary platforms are designed to produce allogeneic "off-the-shelf" therapies that are characterized by durability, scalability, safety, and efficacy. This innovative approach allows for the generation of homogenous and well-characterized cell products, which are essential for efficient manufacturing and therapeutic application.

The iNK cells developed by Shoreline possess innate capabilities to target and eliminate cancer cells while sparing healthy tissues. These cells are genetically engineered to enhance their performance, particularly through the knockout of the CISH gene, which is known to negatively regulate NK cell function. Additionally, the company is exploring the therapeutic potential of engineered iMACs, which can modify the tumor microenvironment and stimulate anti-tumor immune responses. By leveraging their expertise in iPSC technology, Shoreline aims to address a wide range of diseases, including various cancers and inflammatory conditions, thereby pushing the boundaries of cellular immunotherapy.

United States

Shoreline's proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.

Shoreline Biosciences

Company Details